FinnCap reiterated their under review rating on shares of Ekf Diagnostics Holding PLC (LON:EKF) in a report released on Tuesday.

A number of other brokerages also recently weighed in on EKF. N+1 Singer reiterated a corporate rating on shares of Ekf Diagnostics Holding PLC in a research report on Friday, October 7th. Panmure Gordon reiterated a buy rating and issued a GBX 19 ($0.24) price target on shares of Ekf Diagnostics Holding PLC in a research report on Monday, November 7th.

Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.111 on Tuesday. Ekf Diagnostics Holding PLC has a 12 month low of GBX 7.75 and a 12 month high of GBX 18.24. The company’s 50-day moving average is GBX 16.99 and its 200-day moving average is GBX 14.65. The stock’s market capitalization is GBX 73.37 million.

WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at

About Ekf Diagnostics Holding PLC

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company’s point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases.

Receive News & Stock Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related stocks with our FREE daily email newsletter.